TNFRSF17 and plasma cell myeloma: Autologous CAR-T therapies targeting B-cell maturation antigen (BCMA) such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have offered response depths and durations among patients with highly refractory myeloma that would have been unimaginable even 5 years ago.